ADAPY.US Adaptimmune Therapeutics plc

Healthcare Biotechnology USA Stocks
0.0280 USD
Close of Nov 13, 2026
0.0001 0.0700
Market cap
USD 7.42M
P/E
-
P/B
2.68x
ROE
78.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ADAPY.US undervalued?

Graham number

The Graham number of Adaptimmune Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Adaptimmune Therapeutics plc fundamental analysis

No fundamental analysis for Adaptimmune Therapeutics plc yet.

Adaptimmune Therapeutics plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Full company profile